Search
Search titles only
By:
Search titles only
By:
Home
Forums
New posts
Search forums
What's new
New posts
New profile posts
Latest activity
Members
Current visitors
New profile posts
Search profile posts
Log in
Register
Search
Search titles only
By:
Search titles only
By:
New posts
Search forums
Menu
Install the app
Install
Reply to Thread
Guest, we'd love to know what you think about the forum! Take the
Diabetes Forum Survey 2024 »
Home
Forums
Diabetes News and Research
Diabetes News
SGLT2 inhibitors help people with type 2 diabetes live longer and healthier, study says
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Message
<blockquote data-quote="DCUK NewsBot" data-source="post: 1418554" data-attributes="member: 106455"><p>SGLT2 inhibitors, used to treat type 2 diabetes, reduced the rate of being admitted to hospital for heart failure or death from heart failure by 39 per cent, a worldwide study has found. SGLT2 inhibitors are a relatively new type of drug class which was approved for treating type 2 diabetes in 2013. They work by helping the kidneys to lower blood sugar levels. Now a study of more than 300,000 people across six countries has demonstrated significant health benefits of the oral medication compared to other medicines used to treat type 2 diabetes. Bruce Cooper, Vice President and Head of Global Medical Affairs at AstraZeneca, said: "Real-world data from this study provide striking evidence that the newer SGLT-2i class of medicines cuts the rate of hospitalisations for heart failure and death by approximately half. "CVD-REAL is the first study to observe these effects of SGLT-2i treatment in a much broader and lower risk group of type 2 diabetes patients than previously evaluated in clinical trials." The SGLT2 inhibitors investigated during the CVD-REAL study were Forxiga (dapagliflozin), Jardiance (empagliflozin) and Invokana (canagliflozin). More than 90 per cent of people studied were on either Forxiga, mainly prescribed in Europe, or Invokana, primarily taken in the US. Eighty-seven per cent of those studied had no history of cardiovascular disease. The type 2 diabetes treatments that the SGLT2s were compared against included insulin and DPP-4 inhibitors as well as metformin. SGLT-2 drugs were shown to lower the combined risk of hospitalisation for heart failure and death from any cause by 46 per cent. The reduction of admittance to hospital for heart failure or death from heart failure was 39 per cent. Researcher, Dr Mikhail Kosiborod, who is a cardiologist based ay Saint Luke's Mid America Heart Institute located in Kansas City said: "The fact that the results are remarkably consistent from country to country regardless of which compound predominates, that certainly seems to suggest that it's a class effect." The findings were presented at the American College of Cardiology 66th Annual Scientific Session.</p><p></p><p><a href="http://www.diabetes.co.uk/news/2017/mar/sglt2-inhibitors-help-people-with-type-2-diabetes-live-longer-and-healthier,-study-says-95478131.html" target="_blank">Continue reading...</a></p></blockquote><p></p>
[QUOTE="DCUK NewsBot, post: 1418554, member: 106455"] SGLT2 inhibitors, used to treat type 2 diabetes, reduced the rate of being admitted to hospital for heart failure or death from heart failure by 39 per cent, a worldwide study has found. SGLT2 inhibitors are a relatively new type of drug class which was approved for treating type 2 diabetes in 2013. They work by helping the kidneys to lower blood sugar levels. Now a study of more than 300,000 people across six countries has demonstrated significant health benefits of the oral medication compared to other medicines used to treat type 2 diabetes. Bruce Cooper, Vice President and Head of Global Medical Affairs at AstraZeneca, said: "Real-world data from this study provide striking evidence that the newer SGLT-2i class of medicines cuts the rate of hospitalisations for heart failure and death by approximately half. "CVD-REAL is the first study to observe these effects of SGLT-2i treatment in a much broader and lower risk group of type 2 diabetes patients than previously evaluated in clinical trials." The SGLT2 inhibitors investigated during the CVD-REAL study were Forxiga (dapagliflozin), Jardiance (empagliflozin) and Invokana (canagliflozin). More than 90 per cent of people studied were on either Forxiga, mainly prescribed in Europe, or Invokana, primarily taken in the US. Eighty-seven per cent of those studied had no history of cardiovascular disease. The type 2 diabetes treatments that the SGLT2s were compared against included insulin and DPP-4 inhibitors as well as metformin. SGLT-2 drugs were shown to lower the combined risk of hospitalisation for heart failure and death from any cause by 46 per cent. The reduction of admittance to hospital for heart failure or death from heart failure was 39 per cent. Researcher, Dr Mikhail Kosiborod, who is a cardiologist based ay Saint Luke's Mid America Heart Institute located in Kansas City said: "The fact that the results are remarkably consistent from country to country regardless of which compound predominates, that certainly seems to suggest that it's a class effect." The findings were presented at the American College of Cardiology 66th Annual Scientific Session. [url="http://www.diabetes.co.uk/news/2017/mar/sglt2-inhibitors-help-people-with-type-2-diabetes-live-longer-and-healthier,-study-says-95478131.html"]Continue reading...[/url] [/QUOTE]
Verification
Post Reply
Home
Forums
Diabetes News and Research
Diabetes News
SGLT2 inhibitors help people with type 2 diabetes live longer and healthier, study says
Top
Bottom
Find support, ask questions and share your experiences. Ad free.
Join the community »
This site uses cookies. By continuing to use this site, you are agreeing to our use of cookies.
Accept
Learn More.…